This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colmenero, J D Articles by Valverde, E Search for Related Content PubMed PubMed Citation Articles by Colmenero, J D Articles by Valverde, E

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1994 December; 38(12): 2798-2802

Possible implications of doxycycline-rifampin interaction for treatment of brucellosis.

J D Colmenero, L C Fernández-Gallardo, J A Agúndez, J Sedeño, J Benítez and E Valverde

Internal Medicine Department, Málaga Regional Hospital, Spain.

ABSTRACT

We studied the possible interaction between rifampin and doxycycline in 20 patients with brucellosis treated randomly with either doxycycline and streptomycin or doxycycline and rifampin. The doxycycline levels in the plasma of patients in the group treated with rifampin were significantly lower than those in the plasma of patients treated with doxycycline and streptomycin. Furthermore, clearance in patients treated with rifampin was significantly higher than that in patients treated with doxycycline and streptomycin, and consequently, the elimination half-life and the area under the concentration-time curve were significantly lower. There was no therapeutic failure or relapse in the group treated with doxycycline and streptomycin, whereas 2 of 10 patients in the group treated with doxycycline and rifampin had a therapeutic failure or relapse. The plasma doxycycline levels had an inverse correlation with plasma rifampin levels. In the group treated with rifampin, those who were rapid acetylators had lower levels of doxycycline. In conclusion, combined treatment with rifampin reduces the levels of doxycycline in plasma. These data suggest that therapeutic failures or relapses may result from this interaction.

---

Antimicrob Agents Chemother. 1994 December; 38(12): 2798-2802

This article has been cited by other articles:

• Forrest, G. N., Tamura, K. (2010). Rifampin Combination Therapy for Nonmycobacterial Infections. Clin. Microbiol. Rev. 23: 14-34 [Abstract] [Full Text]  
• Sousa, M., Pozniak, A., Boffito, M. (2008). Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother 62: 872-878 [Abstract] [Full Text]  
• Agundez, J. A. G., Golka, K., Martinez, C., Selinski, S., Blaszkewicz, M., Garcia-Martin, E. (2008). Unraveling Ambiguous NAT2 Genotyping Data. Clin. Chem. 54: 1390-1394 [Abstract] [Full Text]  
• Shen, M. W. (2008). Diagnostic and Therapeutic Challenges of Childhood Brucellosis in a Nonendemic Country. Pediatrics 121: e1178-e1183 [Abstract] [Full Text]  
• Pappas, G., Akritidis, N., Bosilkovski, M., Tsianos, E. (2005). Brucellosis. NEJM 352: 2325-2336 [Full Text]  
• (2003). American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis. Am. J. Respir. Crit. Care Med. 167: 603-662 [Full Text]  
• Martinez-Lacasa, J., Cabellos, C., Martos, A., Fernandez, A., Tubau, F., Viladrich, P. F., Linares, J., Gudiol, F. (2002). Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis. J Antimicrob Chemother 49: 507-513 [Abstract] [Full Text]  
• Strayhorn, V. A., Baciewicz, A. M., Self, T. H. (1997). Update on Rifampin Drug Interactions, III. Arch Intern Med 157: 2453-2458 [Abstract]